PQB Stock Overview
A biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pure Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.52 |
| 52 Week High | zł4.61 |
| 52 Week Low | zł1.17 |
| Beta | 1.28 |
| 11 Month Change | 0% |
| 3 Month Change | 22.19% |
| 1 Year Change | -56.26% |
| 33 Year Change | -93.97% |
| 5 Year Change | -71.60% |
| Change since IPO | -63.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| PQB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | -56.3% | -16.9% | 9.1% |
Return vs Industry: PQB underperformed the German Biotechs industry which returned 34.1% over the past year.
Return vs Market: PQB underperformed the German Market which returned 7.5% over the past year.
Price Volatility
| PQB volatility | |
|---|---|
| PQB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PQB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PQB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 56 | n/a | purebiologics.com |
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
Pure Biologics S.A. Fundamentals Summary
| PQB fundamental statistics | |
|---|---|
| Market cap | €6.11m |
| Earnings (TTM) | -€7.33m |
| Revenue (TTM) | €25.21k |
242.4x
P/S Ratio-0.8x
P/E RatioIs PQB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PQB income statement (TTM) | |
|---|---|
| Revenue | zł109.00k |
| Cost of Revenue | zł4.43m |
| Gross Profit | -zł4.32m |
| Other Expenses | zł27.40m |
| Earnings | -zł31.72m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -9.53 |
| Gross Margin | -3,960.55% |
| Net Profit Margin | -29,097.25% |
| Debt/Equity Ratio | 94.7% |
How did PQB perform over the long term?
See historical performance and comparison